Gyre Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs
Gyre Therapeutics, Inc. (GYRE) had Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs of $28.00 thousand as of 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs · last filed 2017-03-08
- 2016-09-30: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $28.00K.
- 2016-06-30: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $130.00K.
- 2016-03-31: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $196.00K.
- 2015-12-31: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $1.16M.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs |
|---|---|
| 2016-09-30 | $28.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $130.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $196.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $1.16M 10-K · filed 2017-03-08 |
| 2015-09-30 | $676.00K 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |